338 related articles for article (PubMed ID: 30683146)
1. The Evaluation of Vitiligous lesions Repigmentation after the Administration of Atorvastatin calcium salt and Simvastatin-acid sodium salt in patients with active vitiligo (EVRAAS), a pilot study: study protocol for a randomized controlled trial.
Niezgoda A; Winnicki A; Kosmalski T; Kowaliszyn B; Krysiński J; Czajkowski R
Trials; 2019 Jan; 20(1):78. PubMed ID: 30683146
[TBL] [Abstract][Full Text] [Related]
2. Topical application of simvastatin acid sodium salt and atorvastatin calcium salt in vitiligo patients. Results of the randomized, double-blind EVRAAS pilot study.
Niezgoda A; Winnicki A; Krysiński J; Niezgoda P; Nowowiejska L; Czajkowski R
Sci Rep; 2024 Jun; 14(1):14612. PubMed ID: 38918590
[TBL] [Abstract][Full Text] [Related]
3. Randomized, double-blind clinical trial to evaluate the efficacy of topical tacalcitol and sunlight exposure in the treatment of adult nonsegmental vitiligo.
Rodríguez-Martín M; García Bustínduy M; Sáez Rodríguez M; Noda Cabrera A
Br J Dermatol; 2009 Feb; 160(2):409-14. PubMed ID: 19016706
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Tacrolimus 0.1% for the Treatment of Facial Vitiligo: A Multicenter Randomized, Double-Blinded, Vehicle-Controlled Study.
Seneschal J; Duplaine A; Maillard H; Passeron T; Andreu N; Lassalle R; Favary C; Droitcourt C; Taïeb A; Ezzedine K
J Invest Dermatol; 2021 Jul; 141(7):1728-1734. PubMed ID: 33549606
[TBL] [Abstract][Full Text] [Related]
5. Ginkgo biloba for the treatment of vitilgo vulgaris: an open label pilot clinical trial.
Szczurko O; Shear N; Taddio A; Boon H
BMC Complement Altern Med; 2011 Mar; 11():21. PubMed ID: 21406109
[TBL] [Abstract][Full Text] [Related]
6. Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo.
Rosmarin D; Passeron T; Pandya AG; Grimes P; Harris JE; Desai SR; Lebwohl M; Ruer-Mulard M; Seneschal J; Wolkerstorfer A; Kornacki D; Sun K; Butler K; Ezzedine K;
N Engl J Med; 2022 Oct; 387(16):1445-1455. PubMed ID: 36260792
[TBL] [Abstract][Full Text] [Related]
7. Does topical tacrolimus ointment enhance the efficacy of narrowband ultraviolet B therapy in vitiligo? A left-right comparison study.
Majid I
Photodermatol Photoimmunol Photomed; 2010 Oct; 26(5):230-4. PubMed ID: 20831696
[TBL] [Abstract][Full Text] [Related]
8. Analysis of interleukin-10 levels in lesions of vitiligo following treatment with topical tacrolimus.
Taher ZA; Lauzon G; Maguiness S; Dytoc MT
Br J Dermatol; 2009 Sep; 161(3):654-9. PubMed ID: 19438859
[TBL] [Abstract][Full Text] [Related]
9. Pimecrolimus cream in repigmentation of vitiligo.
Seirafi H; Farnaghi F; Firooz A; Vasheghani-Farahani A; Alirezaie NS; Dowlati Y
Dermatology; 2007; 214(3):253-9. PubMed ID: 17377388
[TBL] [Abstract][Full Text] [Related]
10. Assessing effectiveness of adding niosomal atorvastatin 1% ointment to topical calcineurin inhibitor treatment in non-segmental vitiligo.
Zartab H; Aflatoonian M; Shamsi-Meymandi S; Pardakhty A; Isazadeh A; Firooz A; Amiri R
J Cosmet Dermatol; 2024 Jun; 23(6):2103-2108. PubMed ID: 38348697
[TBL] [Abstract][Full Text] [Related]
11. Simvastatin versus atorvastatin for improving mild to moderate depression in post-coronary artery bypass graft patients: A double-blind, placebo-controlled, randomized trial.
Abbasi SH; Mohammadinejad P; Shahmansouri N; Salehiomran A; Beglar AA; Zeinoddini A; Forghani S; Akhondzadeh S
J Affect Disord; 2015 Sep; 183():149-55. PubMed ID: 26005776
[TBL] [Abstract][Full Text] [Related]
12. Simvastatin prevents and reverses depigmentation in a mouse model of vitiligo.
Agarwal P; Rashighi M; Essien KI; Richmond JM; Randall L; Pazoki-Toroudi H; Hunter CA; Harris JE
J Invest Dermatol; 2015 Apr; 135(4):1080-1088. PubMed ID: 25521459
[TBL] [Abstract][Full Text] [Related]
13. Microdermabrasion and topical tacrolimus: A novel combination therapy of vitiligo.
Abd-Elazim NE; Yassa HA; Mahran AM
J Cosmet Dermatol; 2020 Jun; 19(6):1447-1455. PubMed ID: 31668003
[TBL] [Abstract][Full Text] [Related]
14. Response of vitiligo to once- vs. twice-daily topical tacrolimus: a controlled prospective, randomized, observer-blinded trial.
Radakovic S; Breier-Maly J; Konschitzky R; Kittler H; Sator P; Hoenigsmann H; Tanew A
J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):951-3. PubMed ID: 19496898
[TBL] [Abstract][Full Text] [Related]
15. Time-kinetic study of repigmentation in vitiligo patients by tacrolimus or pimecrolimus.
Lubaki LJ; Ghanem G; Vereecken P; Fouty E; Benammar L; Vadoud-Seyedi J; Dell'Anna ML; Briganti S; Picardo M; Heenen M
Arch Dermatol Res; 2010 Mar; 302(2):131-7. PubMed ID: 19547993
[TBL] [Abstract][Full Text] [Related]
16. Maintenance therapy of adult vitiligo with 0.1% tacrolimus ointment: a randomized, double blind, placebo-controlled study.
Cavalié M; Ezzedine K; Fontas E; Montaudié H; Castela E; Bahadoran P; Taïeb A; Lacour JP; Passeron T
J Invest Dermatol; 2015 Apr; 135(4):970-974. PubMed ID: 25521460
[TBL] [Abstract][Full Text] [Related]
17. Tacrolimus ointment 0.1% produces repigmentation in patients with vitiligo: results of a prospective patient series.
Tanghetti EA
Cutis; 2003 Feb; 71(2):158-62. PubMed ID: 12635898
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic effects of turmeric topical cream in vitiligo: A randomized, double-blind, placebo-controlled pilot study.
Jalalmanesh S; Mansouri P; Rajabi M; Monji F
J Cosmet Dermatol; 2022 Oct; 21(10):4454-4461. PubMed ID: 35104042
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of ruxolitinib cream 1.5% as an at-home therapy for repigmentation in non-segmental vitiligo.
Agner ML; Parraga SP; Arkhipenko ZM; Pichardo RO; McMichael AJ; Feldman SR
Expert Rev Clin Immunol; 2024 Jul; 20(7):695-702. PubMed ID: 38879876
[TBL] [Abstract][Full Text] [Related]
20. Topical Histamine Stimulates Repigmentation of Nonsegmental Vitiligo by a Receptor-Dependent Mechanism.
Liu J; Xu Y; Lin TK; Lv C; Elias PM; Man MQ
Skin Pharmacol Physiol; 2017; 30(3):139-145. PubMed ID: 28419984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
